2016
Efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes mellitus: systematic review and network meta‐analysis
Abstract: Although they increase the risk of genital infection, SGLT2 inhibitors are effective in improving cardiometabolic markers in type 2 diabetes, with canagliflozin 300 mg performing better in this respect than other inhibitors. Further studies will clarify whether these differences are likely to translate into differing long-term outcomes.
Search citation statements
Paper Sections
Select...
327
95
94
8
Citation Types
33
409
6
34
Year Published
2016
2026
Publication Types
Select...
455
12
11
9
Relationship
1
486
Authors
Journals
Cited by 481 publications
(482 citation statements)
References 72 publications
33
409
6
34
“…Furthermore, it is known that CEC tends to correlate with HDL-C levels [ 27 , 30 ]. However, contrary to ours and most other studies [ 31 ], serum HDL-C tended to decrease after dapagliflozin in that study [ 29 ]. Therefore, whether this difference in HDL-C responses after SGLT2i could have also contributed to the apparent discordant findings in CEC remains to be confirmed with further studies.…”
Section: Discussioncontrasting
confidence: 99%
“…Furthermore, it is known that CEC tends to correlate with HDL-C levels [ 27 , 30 ]. However, contrary to ours and most other studies [ 31 ], serum HDL-C tended to decrease after dapagliflozin in that study [ 29 ]. Therefore, whether this difference in HDL-C responses after SGLT2i could have also contributed to the apparent discordant findings in CEC remains to be confirmed with further studies.…”
Section: Discussioncontrasting
confidence: 99%
“…Luseogliflozin and ipragliflozin were not associated with an increased risk of RTIs. Therefore, not all SGLT-2 inhibitors increased the risk of RTIs, which differed from a previous study ( 6 ). The participants in the luseogliflozin trial were all Japanese, and most of the participants included in the ipragliflozin trial were Japanese.…”
Section: Discussioncontrasting
confidence: 97%
“…The incidence of genital infection was higher with dapagliflozin vs control in the present analysis, and this is consistent with other analyses of dapagliflozin, empagliflozin and canagliflozin . A meta‐analysis comparing all SGLT2 inhibitors with placebo observed a 4 to 6 times increased risk of genital infection with SGLT2 inhibitor use …”
Section: Discussionsupporting
confidence: 92%
